Working… Menu

Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02405585
Recruitment Status : Terminated
First Posted : April 1, 2015
Last Update Posted : February 26, 2019
Information provided by (Responsible Party):
NewLink Genetics Corporation

No Study Results Posted on for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : June 30, 2016
Actual Study Completion Date : July 30, 2016
Certification/Extension First Submitted : February 22, 2019